What is it about?
From the perspective of nephrologists, the pre-authorizations process in Switzerland is cumbersome, not transparent and inequitable, may result in denial or delays of important treatment for patients and contributes to moral distress.
Featured Image
Read the Original
This page is a summary of: Access to expensive therapies and diagnostics for kidney care in Switzerland, Kidney360, July 2024, Wolters Kluwer Health,
DOI: 10.34067/kid.0000000000000522.
You can read the full text:
Contributors
The following have contributed to this page







